Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week.

Sladic

  • After a long downward spiral, Genticel has become part of Genkyotex, one of the companies battling for a piece of the NASH market
  • Takeda has doubled down on Arix with a partnership following its investment in the fund’s IPO
  • Swiss biotech Addex added 3M CHF to its cash pile to extend its runway through 2018
  • Sanofi Pasteur and Medimmune are collaborating on mAbs to fight RSV-related illnesses

Sidarta

  • Asit Biotech has reported positive results from a Phase III trial for a pollen allergy cure
  • TopiVert has begun a Phase I study for its ulcerative colitis treatment
  • Merck KGaA has bagged a priority review for its checkpoint inhibitor, avelumab
  • Sanofi is partnering to launch virtual trials with Science37, an LA-based company
  • Guselkumab from Morphosys, in collaboration with Janssen, met all of its primary endpoints in Phase III for plaque psoriasis

Jiri Foltyn

  • The Chairman of Novartis, Jörg Reinhardt, took a step back from the company’s efforts to make a glucose-sensing smart lens
  • There’s a new Research Institute of Molecular Pathology at the Vienna Biocenter, following a €52M investment from Boehringer Ingelheim

Images from LadyWriter55, Jiri Foltyn, Sidarta, Sladic / shutterstock.com

ADVERTISEMENT
Previous post

UPDATE: French VC has raised the Biggest Green Biotech Fund in Europe

Next post

An HIV Vaccine Eliminates the Virus in a Patient for 7 Months